Psychosomatics 43:171-174, June 2002
© 2002 The Academy of Psychosomatic Medicine
The Role of Atypical Antipsychotics in the Treatment of Delirium
Thomas L. Schwartz, M.D., and
Prakash S. Masand, M.D.
Received August 14, 2001; revised; November 27, 2001; accepted December 27, 2001. From the Department of Psychiatry, S.U.N.Y. Upstate Medical University, Syracuse, New York; and Department of Psychiatry, Duke University, Durham, North Carolina. Address for correspondence and reprints: Dr. Thomas L. Schwartz, Department of Psychiatry, S.U.N.Y. Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210. E-mail; schwartT{at}mailbox.hscsyr.edu
Delirium exemplifies the interface between medicine and psychiatry. It is generally characterized by acute disturbances of consciousness, cognition, and perception that are precipitated by an underlying medical condition. The gold standard of psychiatric treatment is to treat the underlying medical cause and use high-potency antipsychotics to treat the clinical manifestations of delirium. In the early 1990s, a new generation of novel antipsychotics was developed. Their mechanism of action, preferential serotonergic (5HT2a) blockade, results in a markedly lower rate of extrapyramidal side effects, an advantage over the typical, older antipsychotic medications. These agents have been shown to be effective and well tolerated in common psychotic disorders (e.g., schizophrenia or bipolar disorder), but few studies have evaluated them in the treatment of delirium. This paper reviews the pertinent literature and summarizes tentative guidelines for novel antipsychotic use in delirium.
Key Words: Delirium • Antipsychotics
This article has been cited by other articles:
|
|
|
|
 
N. S. Karnik, S. V. Joshi, C. Paterno, and R. Shaw
Subtypes of Pediatric Delirium: A Treatment Algorithm
Psychosomatics,
June 1, 2007;
48(3):
253 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Fann, C. M. Alfano, S. Roth-Roemer, W. J. Katon, and K. L. Syrjala
Impact of Delirium on Cognition, Distress, and Health-Related Quality of Life After Hematopoietic Stem-Cell Transplantation
J. Clin. Oncol.,
April 1, 2007;
25(10):
1223 - 1231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Lyness
End-of-Life Care: Issues Relevant to the Geriatric Psychiatrist
Focus,
January 1, 2007;
5(4):
459 - 471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Lacasse, M. M Perreault, and D. R Williamson
Systematic Review of Antipsychotics for the Treatment of Hospital-Associated Delirium in Medically or Surgically Ill Patients
Ann. Pharmacother.,
November 1, 2006;
40(11):
1966 - 1973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mittal, D. Majithia, R. Kennedy, and J. Rhudy
Differences in Characteristics and Outcome of Delirium as Based on Referral Patterns
Psychosomatics,
October 1, 2006;
47(5):
367 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Straker, P. A. Shapiro, and P. R. Muskin
Aripiprazole in the Treatment of Delirium
Psychosomatics,
October 1, 2006;
47(5):
385 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Catalano, J. W. Grace, M. C. Catalano, M. J. Morales, and L. M. Cruse
Acute Akathisia Associated With Quetiapine Use
Psychosomatics,
August 1, 2005;
46(4):
291 - 301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kato, C. Kawanishi, I. Kishida, T. Furuno, T. Matsumura, H. Hasegawa, and Y. Hirayasu
Delirium Resolving Upon Switching From Risperidone to Quetiapine: Implication of CYP2D6 Genotype
Psychosomatics,
August 1, 2005;
46(4):
374 - 375.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Lyness
End-of-Life Care: Issues Relevant to the Geriatric Psychiatrist
Focus,
April 1, 2005;
3(2):
341 - 353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Bourgeois and D. M. Hilty
Prolonged Delirium Managed With Risperidone
Psychosomatics,
February 1, 2005;
46(1):
90 - 91.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tei, T. Morita, S. Inoue, and H. Miyata
Torsades de Pointes Caused by a Small Dose of Risperidone in a Terminally Ill Cancer Patient
Psychosomatics,
October 1, 2004;
45(5):
450 - 451.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Balas, M. Gale, and S. H. Kagan
Delirium Doulas: An Innovative Approach to Enhance Care for Critically Ill Older Adults
Crit. Care Nurse,
August 1, 2004;
24(4):
36 - 46.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-S. Han and Y.-K. Kim
A Double-Blind Trial of Risperidone and Haloperidol for the Treatment of Delirium
Psychosomatics,
August 1, 2004;
45(4):
297 - 301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vella-Brincat and A D Macleod
Haloperidol in palliative care
Palliative Medicine,
April 1, 2004;
18(3):
195 - 201.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. M. Cohen, E. G. Tessier, M. J. Germain, and N. B. Levy
Update on Psychotropic Medication Use in Renal Disease
Psychosomatics,
February 1, 2004;
45(1):
34 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N Serio
Acute Delirium Associated with Combined Diphenhydramine and Linezolid Use
Ann. Pharmacother.,
January 1, 2004;
38(1):
62 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
Academy of Psychosomatic Medicine.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
